Abstract：【Objective】To compare the clinical efficacy of dosage form 3M and 1M of leuprorelin in the treatment of central precocious puberty (CPP) in girls. 【Methods】A total of 35 children with CPP admitted to the Department of Child Health Care of our hospital from July 2022 to August 2023 were retrospectively analyzed and divided into the observation group (n=17) and the control group (n=18) according to different treatment methods. Sex hormone levels [luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E2)], uterine length, ovarian volume, height, weight, bone age/chronological age of the two groups before and after treatment were compared, and the occurrence of adverse reactions between the two groups were compared. 【Results】There were no significant differences in uterine length, left ovarian volume, right ovarian volume, bone age/actual age, height and body weight index (BMI) between the two groups before and after treatment (P>0.05). After 3 months of treatment, the peak levels of LH and FSH in 2 groups were lower than before treatment, and the difference was statistically significant (P<0.05). After 3 and 6 months of treatment, the levels of serum LH, FSH and E2 in the two groups were lower than before treatment, and the differences were statistically significant (P<0.05). After 3 months of treatment, serum LH and FSH levels in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The two formulations of leuprorelin have similar clinical efficacy and safety in the treatment of CPP girls, and the long-acting formulations are economical and convenient.
周源源, 赵莎. 不同剂型亮丙瑞林治疗女童中枢性性早熟的临床疗效比较*[J]. 医学临床研究, 2024, 41(10): 1472-1474.
ZHOU Yuanyuan, ZHAO Sha. Comparison of Clinical Efficacy of Different Formulations of Leuprorelin in the Treatment of Central Precocious Puberty in Girls. JOURNAL OF CLINICAL RESEARCH, 2024, 41(10): 1472-1474.
[1] 叶枫,金圣娟,杜彩琪,等.亮丙瑞林3M剂型在中枢性性早熟治疗中的有效性及安全性研究进展[J].中华实用儿科临床杂志,2022,37(23):1828-1832.
[2] ECKERT-LIND C, BUSCH A S, PETERSEN J H, et al. Worldwide secular trends in age at pubertal onset assessed by breast development among girls: a systematic review and meta-analysis[J].JAMA Pediatr,2020,174(4):e195881.
[3] BRIX N, ERNST A, LAURIDSEN L L B, et al. Timing of puberty in boys and girls: A population-based study[J].Paediatr Perinat Epidemiol,2019,33(1):70-78.
[4] 董关萍,傅君芬.促性腺激素释放激素类似物在儿童中枢性性早熟中的应用[J].中华实用儿科临床杂志,2021,36(4):241-243.
[5] 中华医学会儿科学分会内分泌遗传代谢学组,中华儿科杂志编辑委员会.中枢性性早熟诊断与治疗专家共识(2022)[J].中华儿科杂志,2023,61(1):16-22.
[6] BANGALORE K K, FUQUA J S, ROGOL A D, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium[J].Horm Res Paediatr,2019,91(6):357-372.
[7] 陈磊,侯彬兰,车玲,等.中枢性性早熟女童采用促性腺激素释放激素类似物治疗前后血清瘦素、脂联素、性激素水平变化及其相关性研究[J].中国性科学,2021,30(7):140-143.
[8] 余丹.醋酸亮丙瑞林治疗小儿性早熟的临床研究[J].中国处方药,2020,18(5):98-99.
[9] 张欣,田明达,陈琳,等.醋酸亮丙瑞林治疗患儿特发性中枢性性早熟中的临床疗效与安全性探讨[J].医学食疗与健康,2021,19(8):8-9.
[10] SHOKRI E, HEIDARIANPOUR A, RAZAVI Z. Positive effect of combined exercise on adipokines levels and pubertal signs in overweight and obese girls with central precocious puberty[J].Lipids Health Dis,2021,20(1):152.
[11] LIU G Y, GUO J X, ZHANG X J, et al. Obesity is a risk factor for central precocious puberty: a case-control study[J].BMC Pediatr,2021,21(1):509.
[12] 王静,沈春荣.体质量指数对中枢性性早熟女童GnRH激发试验结果的影响[J].中国妇幼健康研究,2020,31(4):427-430.
[13] 杨明明,汤涌泉,高钱,等.中枢性性早熟女童使用不同剂型亮丙瑞林治疗的临床疗效观察[J].海南医学院学报,2023,29(22):1718-1723.
2024, Vol. 41 
